Good morning, ladies and gentlemen, and welcome to the DarioHealth First Quarter 2024 Results Conference Call. [Operator Instructions] This call is being recorded on Wednesday, May 15, 2024. I would now like to turn the conference over to Kat Parrella, Investor Relations Manager at Dario. Please go ahead.

Thank you, operator, and good morning, everybody. Thank you for joining us today for a discussion of DarioHealth's First Quarter 2024 Financial Results. Leading the call today will be Erez Raphael, CEO of DarioHealth. He'll be joined by Rick Anderson, President at DarioHealth. After the prepared remarks, we will open the call for Q&A. An audio recording and webcast replay for today's call will also be available online as detailed in the press release invite for this call. For the benefit of those who may be listening to the replay or archived webcast, this call is being held on Wednesday, May 15, 2024. This morning, we issued a press release announcing our financial results for the first quarter of 2024. A copy of the release can be found on the Investor Relations page of DarioHealth's website. Actual events or results may differ materially from those projected as a result of changing market trends, reduced demand or the competitive nature of DarioHealth's industry. Such forward-looking statements and their implications may involve known and unknown risks, uncertainties and other factors that may cause actual results or performance to differ materially from those projected. The forward-looking statements discussed on this call are subject to other risks and uncertainties, including those discussed in the Risk Factors section and elsewhere in the company's first quarter 2024 quarterly report on Form 10-K. Additional information concerning factors that could cause results to differ materially from our forward-looking statements are described in greater detail in the company's press release issued this morning and in the company's other filings with the SEC. In addition, certain non-GAAP financial measures may be discussed during this call. These non-GAAP measures are used by management to make strategic decisions, forecast future results and evaluate the company's current performance. Management believes the presentation of these non-GAAP financial measures is useful for investors' understanding and assessment of the company's ongoing core operations and prospects for the future. A reconciliation of these non-GAAP measures to the most comparable GAAP measures is included in this morning's press release. With that, I'd like to introduce Erez Raphael, Chief Executive Officer at DarioHealth.

Thank you, Kat, and thanks to all of you for joining our call this morning. Q1 2024 represents a major turning point in the scaling of our business and the acceleration of our path to profitability. We are happy to announce that our core B2B2C business channel, which represents recurring revenues mainly from health plans and employers, is continuing to scale up and is now the largest of our 3 revenue channels, accounting for about 71% of our pro forma revenues for the quarter. This is a milestone that we have been working toward for some time. Due to the scale and due to the high SaaS-like gross margins of this revenue stream that is above 75% and should exceed 80% and the faster-than-expected achievement in operational efficiencies post Twill acquisition, we have never been better positioned to reach profitability. I would like to share more information on the clear trends that we see in the business and are adding to our confidence in our ability to scale and reach profitability. First, B2B2C recurring revenue scale, the organic value of revenues this quarter continue to grow alongside the additional revenues from the Twill acquisition, which were added since February 15. Pro forma for Q1, we are at an annual run rate of $31 million for all 3 channels together, where approximately $22 million of this being our core B2B2C business. The legacy value portion of the B2B2C channel revenue grew sequentially over the fourth quarter of 2023 organically by more than 30%. This growth can be attributed to the Aetna platform, expansions of existing contracts and new customer launches. We'll see this growth progress throughout the year with the continuation of our revenue growth from recently launched accounts and multiple new contracts in Q2 and further execution of our pipeline,…

Thanks, Erez. Our B2B2C revenue grew substantially from the fourth quarter of last year to the first quarter of this year as we saw the impact of new customer launches, customer expansions and the impact of the Twill acquisition. We have more than 15 customers launching in Q1 and Q2 of this year, and we have customers from last year's sales cycle continuing to sign contracts into Q2. Both products on the private labeled Aetna platform have launched, and we have seen Aetna continue to add customers to the [indiscernible] platform in Q1 and Q2, a trend we expect to continue with related increases in revenue for the next several quarters. We have signed an agreement to expand with one of our health plan customers through a partner, and we expect to launch that expansion later this year. In addition, we expect to add an additional health plan and a handful of off-cycle self-insured employers throughout the year. The acquisition of Twill also brought a broader opportunity to enable pharmaceutical customers through Twill's patient acquisition and adherence platform. This platform leverages the core Twill platform used by their employer and health plan customers, making the delivery highly efficient and high margin. Twill has a proven track record of its ability to activate patients and increase adherence with several of the largest pharmaceutical companies in the world. Over the last year, they have refined this platform into a licensing model that we expect to bring ARR revenue starting in 2024 from a couple of large pharma companies that are already piloting the solution. And we believe based on early interest and traction that we'll be able to expand this to add significant additional revenue in our recurring ARR B2B2C business by the end of 2024 and into 2025. We are very…

Thank you, Rick. All the strategic decisions that we have made over the last few years are reaching a turning point in the scaling of our business and acceleration towards profitability. Today, the Dario platform is the most consumer-centric, the most comprehensive in terms of conditions covered and has the most proven track record in terms of clinical performance, improving cost savings in this space. Today, Dario has massive client base and book of business, including 3 out of the top 8 national health plans such as Cigna, Elevance and Aetna as well as big name national employers such as Amazon, Google, Microsoft and key pharma companies such as Sanofi, Merck and Eli Lilly, all of which are contributing to our B2B2C revenue, which is growing extensively on a Dario-Twill integrated basis. Another factor that contribute to our confidence reaching cash flow positive next year is the Twill-Dario merger and synergies we're leveraging on. With efficiencies that we mentioned and progressing about a year ahead of our original schedule, on track [ to reach ] even above 30% by the end of the year, we believe that the [ B2B2C ] recurring revenue channel alongside those efficiencies will be the main driver of our acceleration to profitability second half of 2025 at $54 million in revenue. With that, I want to open the call for Q&A session.

[Operator Instructions] Your first question comes from the line of Charles Rhyee of TD Cowen.

This is Adam, on for Charles. Wondering to begin with, has anything changed in the agreement with Sanofi that could affect milestone payments from them over the course of this year? I'm wondering how we should think about timing of the payments in 2024. Looking at the first quarter strategic payments here, I understand that there's lumpiness quarter-to-quarter, and we should be looking at the full year. But I just wanted to come back to that and I wonder what Sanofi looks over the course of this year, if you can share.

Yes, sure. So Adam, thanks for the question. There is no fundamental change in the way that we are executing on the agreement with Sanofi. We do see some additional opportunities with the addition of Twill into our product offering. And we do expect that the addition of Twill is going to create opportunities with Sanofi. So overall, the deal exists. The $30 million deal exists. And yes, they're going to still stay lumpy. But overall, as I stated on the earnings, we are looking on somewhere between $6 million to $8 million in revenue yearly from the strategic channel that is coming from Sanofi or other sources of revenues. So overall, we believe that later this year, we're going to balance the revenue in a way that we're going to be able to see the $6 million to $8 million. Ideally, we will be in a position that we will do, maybe even more than that by having the Twill platform also adopted. And we are having specific discussions about that, not only with Sanofi, but also with other clients that are looking into the addition of Twill into our product offering.

That's helpful. And with regard to the Aetna ramp, obviously, good to see the contribution there this quarter. I'm wondering if you can share, are you seeing utilization volumes there as you'd expected to see so far? And how should we be thinking about that over the course of this year and maybe contributing to revenue through the course of this year?

The -- in terms of what we're seeing with that, as I mentioned on the call, is that we've launched both products actually and the utilization is about what we would expect from that. We expect that they will continue to add customers to the platform throughout the year. As a matter of fact, we're seeing them add essentially every month more people onto the platform, and they are selling through the ASO, employer sales cycle. So we'll expect another group of customers come on midyear and then end of the year. But they're adding every month right now basically to the platform. And the revenue from both of those products is on a PEPM basis. So we are getting paid for everybody who has access to the platform. So it's not a utilization-based contract, but the underlying utilization is more or less what we would have anticipated. Obviously, we're early in the year from that launch but from what we're seeing so far.

And last question would be with regard to the $60 million in signed contract value that you guys have previously talked about, how should we be thinking about that phasing in over the course of this year, maybe next year as well? Are these things that can see maybe in the coming quarters? Or are these opportunities that really phased in over time?

Yes. So thanks for this question. So overall, we believe that it's going to materialize this year and into the kind of first half of next year, we think that we're going to see that. And we will keep building the -- we keep churning signed contracts, and it's being added to the $60 million. So overall, we look at it as something that will be materialized like -- somewhere like mid of next year.

[Operator Instructions] And there are no further questions at this time. I would like to turn it back to Erez Raphael for closing remarks.

I would like to thank everyone. And I'm looking forward to see you in the next quarters where we're going to continue to report on our progress on all the parameters, top line, gross margins, OpEx and bottom line toward our best of profitability. Thanks, everyone.

Ladies and gentlemen, this concludes today's conference call. Thank you for participating. You may now disconnect.